Latest News

EUSA Pharma grants Japanese rights to Erwinase® oncology therapy to Ohara Pharmaceutical
6th July 2010. The agreement represents the first product partnership EUSA has established in Japan...

EUSA Pharma completes establishment of commercial infrastructure with appointment of President for Europe and International region
8th March 2010. EUSA Pharma announced the appointment of Iain McGill to the role of President, Europe and International. The appointment marks the completion of the build of both EUSA’s executive management team and the company’s commercial infrastructure.....

New Informative Website Launched to Help People With Oral Mucositis and Their Carers
25th January 2010. EUSA Pharma announced that from today, a new resource is available to help people with Oral Mucositis: www.mouthsmadegood.com. Oral Mucositis (OM) is a side effect of cancer therapy ....

EUSA Pharma completes the European launch of Caphosol® for prevention and treatment of oral mucositis caused by cancer therapy
31st March 2009. EUSA Pharma announced today the successful completion of its European launch of Caphosol® for the prevention and treatment of oral mucositis associated with cancer therapy, as an adjunct to standard oral care.

EUSA Pharma appoints Chief Financial Officer
18th March 2009. EUSA Pharma announced today the appointment of David Cook to the newly-created role of Chief Financial Officer. Mr Cook will split his time between EUSA’s headquarters in the USA and the UK.

EUSA Chairman awarded “Outstanding Personal Contribution to UK Bioscience” by BIA
22nd January 2009. At its Gala Dinner, the BioIndustry Association (BIA)  presented the sixth BIA Award for Outstanding Personal Contribution to UK Bioscience to Rolf Stahel. The award recognises an individual who has made a significant contribution to the development of bioscience in the UK.

EUSA Pharma announces Change of Board Membership
28th October 2008. EUSA Pharma is pleased to announce the appointment of Nigel Pitchford, MA MBA PhD to the EUSA Pharma Board of Directors.

EUSA Pharma completes acquisition of
Cytogen Corporation
9th May 2008. EUSA Pharma announced today that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen’s shareholders at a special meeting on 8 May.

EUSA Pharma divests monoclonal antibody research business
and early-stage oncology product
1st May 2008. EUSA Pharma announced today that it has divested its monoclonal antibody research business to the French company International Drug Development (IDD). Concurrently, EUSA has divested its recombinant L-asparaginase therapeutic research program for acute lymphoblastic leukemia to the Alizé Pharma Group.

EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
11th March 2008. EUSA Pharma announced announced that it has entered into a definitive agreement to acquire all the outstanding shares of Cytogen Corporation (NASDAQ: CYTO) for $22.6 million.

Novel Rapydan® gains Marketing Authorisation in EU for the
Relief of Pain associated with Needle Puncture and Cannulation
25 February 2008. EUSA Pharma today announced that Rapydan® (70 mg lidocaine/70 mg tetracaine medicated plaster) has now received marketing authorisation in Sweden, the UK, Germany, the Netherlands, France, Spain, Austria, the Czech Republic, Greece, Ireland, Norway and Portugal following the completion of the European Mutual Recognition Procedure.

EUSA Pharma out-licences preclinical-stage human antibody
to GlaxoSmithKline for up to $44 million plus royalties
18 February 2008. EUSA Pharma today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to $44 million, comprising an upfront fee and development milestones, plus royalties on future sales.

EUSA Pharma announces $30 million Debt Facility
12 December 2007. EUSA Pharma announces that it has entered into a $30 million debt facility offered by Merrill Lynch Capital.

EUSA Pharma announces successful conclusion of the EMR Procedure for Rapydan®
18 October 2007. EUSA Pharma announces the successful conclusion of the European Mutual Recognition Procedure for Rapydan®. The procedure completed successfully at the “day 90” target date of 9 October 2007.